UNASSIGNED: In June 2022, a UK supply issue with aciclovir injection (ACV IV) was announced. In order to review and preserve parenteral ACV for those in greatest need, UHBFT pharmacist and virologists implemented a specialist review for patients prescribed more than 48 hours of treatment. This review initially lasted 10 weeks and data was collected on the advice offered, whether it was accepted, and time required completing the review.
UNASSIGNED: AVS rounds halved IV ACV consumption, compared to pre or post intervention levels, with more than half of patients advised to stop or switch to oral therapy. Diagnostics and sampling guidance was offered in one quarter of reviews, whilst the remaining interventions were more stewardship focused. In almost all cases stewardship advice was readily accepted by clinical teams. Due to positive feedback from clinicians and its effective management of supply, the anti-viral stewardship (AVS) programme was re-introduced in June 2023.
UNASSIGNED: Antiviral AMS rounds provide an opportunity to optimise sampling, diagnosis and improve patient management. Introduction of regular AVS at UHBFT are now well established and plan to be implemented in other hospitals.
2022年6月,英国宣布了阿昔洛韦注射液(ACVIV)的供应问题。为了为最有需要的人审查和保存肠胃外ACV,UHBFT药剂师和病毒学家对治疗超过48小时的患者进行了专家审查。这项审查最初持续了10周,并收集了所提供建议的数据,是否被接受,和完成审查所需的时间。
■AVS将IVACV消耗减半,与干预前或干预后的水平相比,超过一半的患者建议停止或改用口服治疗。在四分之一的审查中提供了诊断和抽样指导,而其余的干预措施则更加注重管理。在几乎所有情况下,临床团队都很容易接受管理建议。由于临床医生的积极反馈及其对供应的有效管理,抗病毒管理(AVS)计划于2023年6月重新推出.
■抗病毒AMS轮提供了优化采样的机会,诊断和改善患者管理。在UHBFT引入常规AVS现在已经建立,并计划在其他医院实施。